Patients will be asked to visit the study center 2 times, the first time for clinical assessment and a second time for sample collection. Healthy controls will only be asked to visit the study center for sample collection. A sample of blood and saliva will be collected in order to measure CGRP levels and DNA and hormone testing.

CGRP is a neuropeptide related to migraine pathophysiology, which can be found in human saliva in both patients and healthy controls. The differences in CGRP levels may help us explain the differences in the treatment response.

A sample of saliva will be collected in order to measure CGRP levels and a blood sample will be collected in order to conduct a DNA test and hormones test.

Inclusion Criteria:

• Migraine patients according to ICHD-3 criteria
• Healthy controls paired to patient age and sex, without headache and without first degree family history of headache.

Exclusion Criteria:

• Presence of any major medical or neurological illness.
• Presence of any salivary gland malfunction.
• Abuse or dependence to tobacco, alcohol or any drug in the previous 12 months before the enrollment.
• Active migraine preventive treatment.
• Pregnant or breastfeeding female.

Only cis-gender male and female will be included in the study due to hormone testing.

Males and females otherwise healthy with episodic and chronic migraine in different age groups will be included in the study. Controls matching age and sex will be selected for the control groups.